Vol 10, Supp. G (2014)
suplement
Published online: 2015-03-20
Page views 1059
Article views/downloads 1546
Get Citation

Connect on Social Media

Connect on Social Media

Treatment with erlotinib in 58-year old woman with liver damage and depression as the first sign of metastases to the central nervous system

Marcin Gołecki

Abstract

Molecularly targeted therapy with EGFR tyrosine kinase inhibitors has become an important enhancement of systemic non-small cell lung cancer therapy in recent years. Current standards strongly recommend this treatment if EGFR activating mutations are present in lung cancer cells. In this article the case of a patient with non-small cell lung cancer and positive EGFR activating mutations is described, who was treated with erlotinib despite liver damage, achieved long-lasting regression in the lungs, the reduction of the transaminases activity in the course of treatment and finally depression as a first sign of the central nervous system progression.

Article available in PDF format

Purchase Subscription